791644-59-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-5-(3-pyridinyloxy)benzenamine is used as a key intermediate in the synthesis of new drugs. Its unique structure allows for the introduction of specific functional groups into drug molecules, potentially enhancing their therapeutic properties and effectiveness.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Fluoro-5-(3-pyridinyloxy)benzenamine serves as a building block for the development of new pesticides and herbicides. Its incorporation into these compounds can lead to improved efficacy and selectivity, reducing the environmental impact of these chemicals.
Used as a Reagent in Organic Chemistry Reactions:
3-Fluoro-5-(3-pyridinyloxy)benzenamine is also utilized as a reagent in various organic chemistry reactions. Its ability to introduce specific functional groups into molecules makes it a valuable tool for researchers and chemists in the synthesis of complex organic compounds.
Overall, the diverse applications of 3-Fluoro-5-(3-pyridinyloxy)benzenamine highlight its importance as a versatile and useful compound in various fields, including pharmaceuticals, agrochemicals, and organic chemistry.

Upstream product

• 2265-94-3 1,3-difluoro-5-nitrobenzene 
• 109-00-2 3-HYDROXYPYRIDINE 
• 803700-29-0 3-(3-fluoro-5-nitrophenoxy)pyridine 

Downstream Products

• 1245607-31-1 2-(3-fluoro-5-(pyridin-3-yloxy)phenyl)isoindoline-1,3-dione 
• 1245607-46-8 methyl 2-(N-(3-fluoro-5-(pyridin-3-yloxy)phenyl)sulfamoyl)benzoate 
• 1245607-47-9 N-(3-fluoro-5-(pyridin-3-yloxy)phenyl)-2-(hydroxymethyl)benzenesulfonamide 
• 1245607-30-0 2-(3-fluoro-5-(pyridin-3-yloxy)phenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide 
• 1241384-85-9 C₁₈H₁₃F₂N₃O₂ 

Relevant academic research and scientific papers

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed nonacidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these noncarboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

NOVEL ISOINDOLIN-1-ONE DERIVATIVE

The present invention relates to a compound represented by formula (I): (wherein R1, R2, R3 and R4 each independently represent a hydrogen or halogen atom; R5 and R6 each independently represent a hydrogen atom or lower alkyl or together represent oxo; X represents C(O) or the like; Y represents an oxygen atom or the like; Z represents a hydrogen atom or the like; R represents 5- or 6-membered heteroaryl having 1-3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms, contained within a ring, or the like) or to a pharmaceutically acceptable salt thereof.

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin

We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: A highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2- yl)benzonitrile 2 led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H- tetrazol-5-yl}pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability. Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability.